ModerateDirect oral anticoagulants (factor Xa inhibitors)×SNRI (serotonin-norepinephrine reuptake inhibitor)
Updated · Methodology
Mechanism
Edoxaban selectively, directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Drugs that inhibit serotonin uptake may reduce platelet function, and the risk of bleeding may increase in patients taking venlafaxine (venlafaxine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With an anticoagulant, venlafaxine may increase the risk of bleeding, possibly through its effect on serotonin release by platelets (US venlafaxine prescribing information, US Food and Drug Administration, FDA). Venlafaxine belongs to the serotonin and noradrenaline reuptake inhibitors (SNRIs). The edoxaban SmPC warns that, as with other anticoagulants, SNRIs may raise the risk of bleeding through their reported effect on platelets (EMA). No clinical or pharmacokinetic data are available for edoxaban with these antidepressants (European Heart Rhythm Association practical guide, EHRA 2021).
Symptoms
The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). Bleeding linked to selective serotonin reuptake inhibitors and serotonin and noradrenaline reuptake inhibitors ranges from bruising, haematomas, nosebleeds and petechiae to life-threatening gastrointestinal bleeding (venlafaxine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The combination is not contraindicated, but, as with other anticoagulants, use edoxaban with caution in patients at increased risk of bleeding (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). As with other serotonin reuptake inhibitors, use venlafaxine with caution in patients predisposed to bleeding, including those taking anticoagulants (venlafaxine SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). When venlafaxine is started or stopped in a patient taking an anticoagulant, monitor closely for bleeding. Warn the patient about the increased risk of bleeding (US venlafaxine prescribing information, US Food and Drug Administration, FDA). The European Heart Rhythm Association (EHRA) states that caution is required, especially with polypharmacy or with two or more bleeding risk factors. Examples include antiplatelet drugs, non-steroidal anti-inflammatory drugs, systemic steroids, previous bleeding or a predisposition to it (anaemia, thrombocytopenia), severe frailty and risk of falls (EHRA 2021). Promptly evaluate any signs or symptoms of blood loss (US edoxaban prescribing information, FDA). With edoxaban, standard coagulation tests change little and vary widely, so they are not useful for monitoring its effect (edoxaban SmPC, EMA). Haemoglobin and haematocrit may help detect hidden bleeding. If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Effexor XR (venlafaxine) prescribing information (2023)– FDA label, Viatris Specialty LLC, DailyMed setid c848a5d8-ba94-4c84-80e3-0bf35fb8e32e, revised 08/2023, sections 5.4, 7 and 17
- EHRA: 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (2021)– Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612–1676, Tables 5–8 and Figure 6
- AEMPS: Ficha técnica: Vandral Retard 75 mg, venlafaxina (nº registro 62401), sección 4.4 (2024)– AEMPS, CIMA, nº registro 62401, revisión 05/2024, sección 4.4
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), secciones 4.4 y 4.5 (2025)– EMA, ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), EU/1/15/993, texto en CIMA nº registro 115993018, información del producto de la EMA actualizada 27/08/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.2